419 related articles for article (PubMed ID: 30150983)
1. The Paradoxical Role of NKG2D in Cancer Immunity.
Sheppard S; Ferry A; Guedes J; Guerra N
Front Immunol; 2018; 9():1808. PubMed ID: 30150983
[TBL] [Abstract][Full Text] [Related]
2. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.
Sheppard S; Guedes J; Mroz A; Zavitsanou AM; Kudo H; Rothery SM; Angelopoulos P; Goldin R; Guerra N
Nat Commun; 2017 Jan; 8():13930. PubMed ID: 28128200
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
5. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
6. NKG2D and its ligands.
Obeidy P; Sharland AF
Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
[TBL] [Abstract][Full Text] [Related]
7. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
9. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
10. Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E; McLeish E; Blancafort P; Coudert JD; Gaudieri S
Front Immunol; 2021; 12():712722. PubMed ID: 34456921
[TBL] [Abstract][Full Text] [Related]
11. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
13. NKG2D in NK and T cell-mediated immunity.
Ogasawara K; Lanier LL
J Clin Immunol; 2005 Nov; 25(6):534-40. PubMed ID: 16380817
[TBL] [Abstract][Full Text] [Related]
14. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice.
Lin Z; Wang C; Xia H; Liu W; Xiao W; Qian L; Jia X; Ding Y; Ji M; Gong W
Immunology; 2014 Mar; 141(3):401-15. PubMed ID: 24708417
[TBL] [Abstract][Full Text] [Related]
15. A disease-linked
Zuo J; Willcox CR; Mohammed F; Davey M; Hunter S; Khan K; Antoun A; Katakia P; Croudace J; Inman C; Parry H; Briggs D; Malladi R; Willcox BE; Moss P
Sci Signal; 2017 May; 10(481):. PubMed ID: 28559451
[TBL] [Abstract][Full Text] [Related]
16. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
17. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
18. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
19. NKG2D Receptor and Its Ligands in Host Defense.
Lanier LL
Cancer Immunol Res; 2015 Jun; 3(6):575-82. PubMed ID: 26041808
[TBL] [Abstract][Full Text] [Related]
20. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.
Kamimura H; Yamagiwa S; Tsuchiya A; Takamura M; Matsuda Y; Ohkoshi S; Inoue M; Wakai T; Shirai Y; Nomoto M; Aoyagi Y
J Hepatol; 2012 Feb; 56(2):381-8. PubMed ID: 21756848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
